341 related articles for article (PubMed ID: 24386667)
1. Long way down--pharmaceutical companies fear falling off 'patent cliff'.
Sklan A
Pharm Pat Anal; 2012 Jul; 1(3):240. PubMed ID: 24386667
[No Abstract] [Full Text] [Related]
2. Indian biogenerics industry emerges.
Jayaraman KS
Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378
[No Abstract] [Full Text] [Related]
3. Drug costs threaten patent protection.
Cimons M
Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
[No Abstract] [Full Text] [Related]
4. Patent cliff mitigation strategies: giving new life to blockbusters.
Kakkar AK
Expert Opin Ther Pat; 2015; 25(12):1353-9. PubMed ID: 26372691
[TBL] [Abstract][Full Text] [Related]
5. The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be valid.
Garrigues A
J Law Med Ethics; 2004; 32(1):181-4. PubMed ID: 15152443
[No Abstract] [Full Text] [Related]
6. Patent watch.
Harrison C
Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462
[No Abstract] [Full Text] [Related]
7. Patent watch: the patent cliff steepens.
Harrison C
Nat Rev Drug Discov; 2011 Jan; 10(1):12-3. PubMed ID: 21193859
[No Abstract] [Full Text] [Related]
8. Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
Fogel LE; Ray CJ
Expert Opin Ther Pat; 2015 Jan; 25(1):1-4. PubMed ID: 25363310
[TBL] [Abstract][Full Text] [Related]
9. Bill C-30: who wins and who loses in Canada's pharmaceutical patent battles?
Hollis A
Expert Opin Ther Pat; 2018 Jan; 28(1):1-3. PubMed ID: 28974123
[No Abstract] [Full Text] [Related]
10. [What drug companies actually do].
Tonby K
Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1806. PubMed ID: 17599137
[No Abstract] [Full Text] [Related]
11. Going over the patent cliff.
Schommer JC
Minn Med; 2011 Oct; 94(10):42-3. PubMed ID: 23256283
[No Abstract] [Full Text] [Related]
12. Pharmaceuticals and medical devices: business practices.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396
[No Abstract] [Full Text] [Related]
13. Preliminary injunctions in generic and branded patent litigation.
Cohen S; England P
Expert Opin Ther Pat; 2013 Sep; 23(9):1083-6. PubMed ID: 23855903
[No Abstract] [Full Text] [Related]
14. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
15. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
16. Pharmaceuticals and medical devices: cost savings. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
[No Abstract] [Full Text] [Related]
17. Canada to change patent law to allow export of cheap drugs.
Kondro W
Lancet; 2003 Oct; 362(9392):1290. PubMed ID: 14577437
[No Abstract] [Full Text] [Related]
18. Drug patent protection: how long is long enough?
Sibbald B
CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
[No Abstract] [Full Text] [Related]
19. Statin utilisation--recognising the role of the invisible hand.
Minhas R
Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171
[No Abstract] [Full Text] [Related]
20. The Impact of Off-Patent Drug Acquisitions on Prices.
Gupta R; Henkel A; Forman HP; Ross JS
J Gen Intern Med; 2018 Jul; 33(7):1007-1009. PubMed ID: 29687433
[No Abstract] [Full Text] [Related]
[Next] [New Search]